Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
9.38 USD | -4.09% |
|
-9.98% | -44.99% |
Kurzporträt
Mitarbeiterzahl: 120
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Carol Suh
FOU | Founder | 33 | 01.11.19 |
Henry Gosebruch
CEO | Chief Executive Officer | 51 | 18.07.23 |
Paul Berns
FOU | Founder | 57 | 01.11.19 |
Joshua Pinto
DFI | Director of Finance/CFO | 38 | 01.06.21 |
Raj Manchanda
CTO | Chief Tech/Sci/R&D Officer | 58 | 01.07.23 |
Nicholas Brandon
CTO | Chief Tech/Sci/R&D Officer | 50 | 01.04.20 |
Robert Lenz
CTO | Chief Tech/Sci/R&D Officer | - | 10.10.23 |
Corporate Officer/Principal | 48 | 01.08.21 | |
Amy Sullivan
HRO | Human Resources Officer | - | 01.01.21 |
Lori Houle
PRN | Corporate Officer/Principal | 57 | 01.04.21 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Paul Berns
FOU | Founder | 57 | 01.11.19 |
May Kin Ho
BRD | Director/Board Member | 71 | 01.04.21 |
Kristina Burow
BRD | Director/Board Member | 50 | 01.01.20 |
Matthew Fust
BRD | Director/Board Member | 59 | 01.12.20 |
Henry Gosebruch
CEO | Chief Executive Officer | 51 | 18.07.23 |
Alaa Halawa
BRD | Director/Board Member | 42 | 01.09.21 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 159 523 997 | 114 732 490 ( 71,92 %) | 0 | 71,92 % |
Unternehmenskontakt
![Straße Neumora Therapeutics, Inc.(NMRA)](https://cdn.zonebourse.com/static/address/159308146.png)
Sektor
![Analystenschätzungen](/images/consensus_flch.gif)
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
-44.99% | 1.5 Mrd. | |
+38.66% | 52.85 Mrd. | |
+35.45% | 38.24 Mrd. | |
-7.81% | 38.87 Mrd. | |
-10.77% | 26.79 Mrd. | |
+11.77% | 26.16 Mrd. | |
-17.82% | 19.9 Mrd. | |
+35.09% | 13.18 Mrd. | |
+29.17% | 12.24 Mrd. | |
-3.05% | 11.79 Mrd. |
- Börse
- Aktien
- A3EVX4 Aktie
- Unternehmen Neumora Therapeutics, Inc.